Return on capital (ROC) is after tax rate of return on net business assets. ROIC is unaffected by changes in interest rates or company debt and equity structure. It measures business productivity performance.
Return on Invested Capital (ROIC)
| Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net operating profit after taxes (NOPAT)1 | 9,050) | 5,607) | 5,941) | 5,865) | 4,332) | |
| Invested capital2 | 36,837) | 34,570) | 33,534) | 29,729) | 27,635) | |
| Performance Ratio | ||||||
| ROIC3 | 24.57% | 16.22% | 17.72% | 19.73% | 15.68% | |
| Benchmarks | ||||||
| ROIC, Competitors4 | ||||||
| Abbott Laboratories | 11.30% | — | — | — | — | |
| Elevance Health Inc. | 11.26% | — | — | — | — | |
| Intuitive Surgical Inc. | 37.63% | — | — | — | — | |
| Medtronic PLC | 5.59% | — | — | — | — | |
| UnitedHealth Group Inc. | 13.51% | — | — | — | — | |
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).
1 NOPAT. See details »
2 Invested capital. See details »
3 2021 Calculation
ROIC = 100 × NOPAT ÷ Invested capital
= 100 × 9,050 ÷ 36,837 = 24.57%
4 Click competitor name to see calculations.
The financial performance between 2017 and 2021 demonstrates a general upward trajectory in capital efficiency, characterized by significant expansion in operating profitability despite a steady increase in the capital base.
- Net Operating Profit After Taxes (NOPAT)
- A substantial increase in NOPAT is observed, growing from 4,332 million USD in 2017 to 9,050 million USD in 2021. While there was a marginal decline in 2020 to 5,607 million USD, the subsequent surge in 2021 represents the most significant period of growth in the analyzed window, indicating a strong acceleration of core operating profitability.
- Invested Capital
- Invested capital exhibited consistent year-over-year growth throughout the period. Starting at 27,635 million USD in 2017, the capital base expanded to 36,837 million USD by 2021. This steady upward trend suggests continuous investment in operational infrastructure and capacity.
- Return on Invested Capital (ROIC)
- ROIC fluctuated between 2017 and 2020, ranging from 15.68% to 19.73%, reflecting a period where the growth in invested capital occasionally outpaced the growth in operating profits. However, 2021 marked a peak in efficiency with an ROIC of 24.57%. This indicates that the returns generated from the invested capital accelerated significantly, far exceeding the rate of capital expansion.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Decomposition of ROIC
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).
1 Operating profit margin (OPM). See calculations »
2 Turnover of capital (TO). See calculations »
3 Effective cash tax rate (CTR). See calculations »
Between 2017 and 2021, the Return on Invested Capital (ROIC) exhibited a general upward trajectory, increasing from 15.68% to 24.57%. This growth reflects an improvement in the ability to generate returns from deployed capital, with a particularly sharp acceleration observed in the final year of the period.
- Operating Profit Margin (OPM)
- The operating profit margin remained relatively stable between 2017 and 2020, fluctuating within a narrow range between 13.80% and 15.39%. However, a substantial increase occurred in 2021, where the margin rose to 19.56%. This expansion indicates a significant improvement in operational efficiency and profitability per dollar of revenue, serving as the primary driver for the surge in ROIC during the final year.
- Turnover of Capital (TO)
- Capital turnover displayed minimal volatility over the five-year duration, beginning at 1.58 in 2017 and ending at 1.59 in 2021. A slight contraction was noted between 2018 and 2020, reaching a low of 1.49. The stability of this ratio suggests that revenue generation relative to the invested capital base has remained constant, indicating that ROIC growth was not driven by gains in asset utilization efficiency.
- Tax Efficiency (1 – Effective Cash Tax Rate)
- The after-tax retention component showed an overall increase from 70.31% in 2017 to 78.74% in 2021. A peak was reached in 2019 at 82.91%. The general upward movement in this metric implies a reduction in the effective cash tax burden, which provided a consistent supportive tailwind to the after-tax return on invested capital.
The decomposition of ROIC reveals that the increase in returns was primarily propelled by expanded operating margins and improved tax efficiency. The consistency of the turnover ratio indicates that the gains in ROIC were achieved through profitability and tax optimization rather than through an increase in the velocity of capital employment.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Operating Profit Margin (OPM)
| Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net operating profit after taxes (NOPAT)1 | 9,050) | 5,607) | 5,941) | 5,865) | 4,332) | |
| Add: Cash operating taxes2 | 2,444) | 1,505) | 1,225) | 1,319) | 1,829) | |
| Net operating profit before taxes (NOPBT) | 11,493) | 7,112) | 7,166) | 7,184) | 6,161) | |
| Revenues | 58,752) | 51,533) | 51,336) | 46,677) | 43,614) | |
| Profitability Ratio | ||||||
| OPM3 | 19.56% | 13.80% | 13.96% | 15.39% | 14.13% | |
| Benchmarks | ||||||
| OPM, Competitors4 | ||||||
| Abbott Laboratories | 20.37% | — | — | — | — | |
| Elevance Health Inc. | 6.58% | — | — | — | — | |
| Intuitive Surgical Inc. | 33.56% | — | — | — | — | |
| Medtronic PLC | 16.48% | — | — | — | — | |
| UnitedHealth Group Inc. | 8.33% | — | — | — | — | |
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).
1 NOPAT. See details »
2 Cash operating taxes. See details »
3 2021 Calculation
OPM = 100 × NOPBT ÷ Revenues
= 100 × 11,493 ÷ 58,752 = 19.56%
4 Click competitor name to see calculations.
The financial trajectory from 2017 to 2021 is characterized by consistent revenue growth and a significant expansion in operating efficiency during the final year of the analyzed period.
- Revenue Trajectory
- Revenues demonstrated a steady upward trend, increasing from US$ 43,614 million in 2017 to US$ 58,752 million in 2021. While growth was consistent through 2019, a period of relative stagnation occurred between 2019 and 2020, where revenues only marginally increased from US$ 51,336 million to US$ 51,533 million, before accelerating again in 2021.
- Net Operating Profit Before Taxes (NOPBT)
- NOPBT grew from US$ 6,161 million in 2017 to US$ 7,184 million in 2018. For the following three years, operating profit remained nearly flat, ending 2020 at US$ 7,112 million. A substantial surge is observed in 2021, with NOPBT rising to US$ 11,493 million, indicating a sharp increase in the absolute volume of operating earnings.
- Operating Profit Margin (OPM) Trends
- The operating profit margin exhibited volatility between 2017 and 2020, rising to 15.39% in 2018 before gradually contracting to 13.80% by 2020. This period of compression suggests that operating expenses grew at a pace that offset revenue gains. However, 2021 saw a significant margin expansion to 19.56%. The divergence between the moderate revenue growth and the substantial increase in NOPBT during 2021 points to enhanced operational leverage and a marked improvement in cost efficiency.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Turnover of Capital (TO)
| Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Revenues | 58,752) | 51,533) | 51,336) | 46,677) | 43,614) | |
| Invested capital1 | 36,837) | 34,570) | 33,534) | 29,729) | 27,635) | |
| Efficiency Ratio | ||||||
| TO2 | 1.59 | 1.49 | 1.53 | 1.57 | 1.58 | |
| Benchmarks | ||||||
| TO, Competitors3 | ||||||
| Abbott Laboratories | 0.69 | — | — | — | — | |
| Elevance Health Inc. | 2.14 | — | — | — | — | |
| Intuitive Surgical Inc. | 1.27 | — | — | — | — | |
| Medtronic PLC | 0.42 | — | — | — | — | |
| UnitedHealth Group Inc. | 2.04 | — | — | — | — | |
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).
1 Invested capital. See details »
2 2021 Calculation
TO = Revenues ÷ Invested capital
= 58,752 ÷ 36,837 = 1.59
3 Click competitor name to see calculations.
Between 2017 and 2021, revenues experienced a consistent upward trajectory, growing from 43,614 million US$ to 58,752 million US$. This growth was accompanied by a steady increase in invested capital, which rose from 27,635 million US$ in 2017 to 36,837 million US$ by the end of 2021, indicating continuous investment in the company's asset base.
- Turnover of Capital Trend
- The turnover of capital exhibited a gradual decline from 2017 to 2020, moving from 1.58 to 1.49. This downward trend suggests that during this four-year period, the expansion of invested capital slightly outpaced the growth in revenue, leading to a marginal decrease in the efficiency of capital utilization.
- Efficiency Recovery in 2021
- A significant reversal in the trend occurred in 2021, with the turnover of capital increasing to 1.59. This recovery was driven by a sharp rise in revenues that exceeded the rate of capital investment, resulting in the highest capital turnover efficiency recorded within the analyzed period.
- Capital Utilization Dynamics
- The relationship between revenue growth and capital investment remained relatively stable, with the turnover ratio fluctuating within a narrow range of 0.10. The rebound in 2021 indicates an improved ability to generate sales from the existing and newly deployed capital base.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Effective Cash Tax Rate (CTR)
| Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net operating profit after taxes (NOPAT)1 | 9,050) | 5,607) | 5,941) | 5,865) | 4,332) | |
| Add: Cash operating taxes2 | 2,444) | 1,505) | 1,225) | 1,319) | 1,829) | |
| Net operating profit before taxes (NOPBT) | 11,493) | 7,112) | 7,166) | 7,184) | 6,161) | |
| Tax Rate | ||||||
| CTR3 | 21.26% | 21.16% | 17.09% | 18.36% | 29.69% | |
| Benchmarks | ||||||
| CTR, Competitors4 | ||||||
| Abbott Laboratories | 20.05% | — | — | — | — | |
| Elevance Health Inc. | 20.22% | — | — | — | — | |
| Intuitive Surgical Inc. | 11.76% | — | — | — | — | |
| Medtronic PLC | 18.59% | — | — | — | — | |
| UnitedHealth Group Inc. | 20.32% | — | — | — | — | |
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).
1 NOPAT. See details »
2 Cash operating taxes. See details »
3 2021 Calculation
CTR = 100 × Cash operating taxes ÷ NOPBT
= 100 × 2,444 ÷ 11,493 = 21.26%
4 Click competitor name to see calculations.
The financial data from 2017 to 2021 indicates a period of significant growth in operating profitability accompanied by fluctuations in the effective cash tax burden. While operational earnings saw a substantial increase over the five-year horizon, the cash tax rate experienced an initial sharp decline before stabilizing at a moderate level.
- Net Operating Profit Before Taxes (NOPBT)
- Operating profitability demonstrated a strong upward trend, growing from US$ 6,161 million in 2017 to US$ 11,493 million in 2021. Profitability remained relatively stagnant between 2018 and 2020, with values hovering around US$ 7,100 million, followed by a sharp acceleration in 2021, where NOPBT increased by approximately 61.7% over the previous year.
- Cash Operating Taxes
- Cash tax payments exhibited a U-shaped trajectory. Outflows decreased from US$ 1,829 million in 2017 to a period low of US$ 1,225 million in 2019. This trend reversed in 2020, with cash taxes rising to US$ 1,505 million and peaking at US$ 2,444 million in 2021, mirroring the surge in operating profits.
- Effective Cash Tax Rate (CTR)
- The effective cash tax rate showed significant volatility in the early part of the period, dropping from a high of 29.69% in 2017 to 17.09% in 2019. Following this decline, the rate shifted upward and remained remarkably stable over the final two years, recording 21.16% in 2020 and 21.26% in 2021. This suggests a normalization of the cash tax burden relative to operating profits after the volatility observed between 2017 and 2019.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?